Capital Royalty Purchases Interest in Royalty Portfolio

In the fourth quarter of 2009, a global pharmaceutical company sold a royalty interest in two leading drugs targeting different therapeutic areas to a consortium of investors (including Capital Royalty) for more than $100 million.

The ease and success of the transaction – in part due to Capital Royalty’s innovative due diligence techniques and creativity in targeting optimal risk-adjusted returns for Capital Royalty’s limited partners – helped contribute to a strong partnership between Capital Royalty and the seller, which has led to additional investment opportunities.